Significant disparities emerge between American and Trans-Atlantic malignant tumor treatment approaches . Generally , the US system is based on a highly private model, which often produce quicker availability to novel interventions, but at a potentially increased price. Conversely , Continental approaches tend to a more comprehensive system, priori